Pyronaridine-Artesunate (Pyramax) for Treatment of Artemisinin- and Piperaquine-Resistant Plasmodium falciparum in the Central Highlands of Vietnam
Nguyen Duc Manh, Nguyễn Văn Thành, Huynh Hong Quang, Nguyen Thị Thanh Van, Nguyễn Ngọc San, Nguyen Chinh Phong, Geoffrey W. Birrell, Michael D. Edstein, Kimberly A. Edgel, Nicholas J. Martin, Marina Chavchich
Abstract
The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine in Vietnam justifies the need to evaluate alternative artemisinin-based combination therapies. Between July 2018 and October 2019, a single-arm trial of pyronaridine-artesunate (Pyramax, PA) was conducted in Dak Nong province, Vietnam.
Topics & Concepts
PiperaquineArtesunateArtemisininPlasmodium falciparumMedicineDihydroartemisininInternal medicineMalariaGastroenterologyPharmacologyImmunologyMalaria Research and ControlComputational Drug Discovery MethodsDrug-Induced Hepatotoxicity and Protection